Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Condition:   Diffuse Large B-Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Biological: Rituximab Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials